ONI Oragenics,

ONI BioPharma Inc. (AMEX: ONI) announced today that it has launched the official ProBiora3 website at www.probiora3.com. This business-to-business website is directed at large mass merchandisers and companies seeking private label products containing the Company's ProBiora3 ingredient, an all natural probiotic blend for oral health. ONI BioPharma's first direct-to-consumer sales website for its own EvoraPlus(TM) oral care product is expected to be launched shortly under the domain name www.evoraplus.com. The Company anticipates that the EvoraPlus website will be the first of several planned direct-to-consumer sales sites for a group of oral care products manufactured by and for ONI containing the Company's probiotic ingredient, ProBiora3.

About ONI BioPharma Inc.

ONI BioPharma Inc. is a biopharmaceutical company with a pipeline of unique proprietary technologies, some of which are being commercialized. The Company also has a number of products in discovery, preclinical and clinical development, with a concentration in the main therapeutic area of infectious diseases, diagnostics, and oral health. The Company has developed platform technologies with respect to its products, thereby creating a pipeline of future products, which the Company expects to develop.

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect ONI BioPharma's current views with respect to future events and financial performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to those set forth in our most recently filed annual report on Form 10-KSB and quarterly report on Form 10-Q, and other factors detailed from time to time in filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.

Contact: ONI BioPharma Inc. Stanley B. Stein 386-418-4018 X222 www.oragenics.com